163 related articles for article (PubMed ID: 27190598)
1. Structural Requirements and Docking Analysis of Amidine-Based Sphingosine Kinase 1 Inhibitors Containing Oxadiazoles.
Houck JD; Dawson TK; Kennedy AJ; Kharel Y; Naimon ND; Field SD; Lynch KR; Macdonald TL
ACS Med Chem Lett; 2016 May; 7(5):487-92. PubMed ID: 27190598
[TBL] [Abstract][Full Text] [Related]
2. Development of amidine-based sphingosine kinase 1 nanomolar inhibitors and reduction of sphingosine 1-phosphate in human leukemia cells.
Kennedy AJ; Mathews TP; Kharel Y; Field SD; Moyer ML; East JE; Houck JD; Lynch KR; Macdonald TL
J Med Chem; 2011 May; 54(10):3524-48. PubMed ID: 21495716
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationship studies and in vivo activity of guanidine-based sphingosine kinase inhibitors: discovery of SphK1- and SphK2-selective inhibitors.
Patwardhan NN; Morris EA; Kharel Y; Raje MR; Gao M; Tomsig JL; Lynch KR; Santos WL
J Med Chem; 2015 Feb; 58(4):1879-1899. PubMed ID: 25643074
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a Small Side Cavity in Sphingosine Kinase 2 that Enhances Inhibitor Potency and Selectivity.
Sibley CD; Morris EA; Kharel Y; Brown AM; Huang T; Bevan DR; Lynch KR; Santos WL
J Med Chem; 2020 Feb; 63(3):1178-1198. PubMed ID: 31895563
[TBL] [Abstract][Full Text] [Related]
5. Structure-Activity Relationship Studies and Molecular Modeling of Naphthalene-Based Sphingosine Kinase 2 Inhibitors.
Congdon MD; Kharel Y; Brown AM; Lewis SN; Bevan DR; Lynch KR; Santos WL
ACS Med Chem Lett; 2016 Mar; 7(3):229-34. PubMed ID: 26985306
[TBL] [Abstract][Full Text] [Related]
6. Probing the substitution pattern of indole-based scaffold reveals potent and selective sphingosine kinase 2 inhibitors.
Congdon M; Fritzemeier RG; Kharel Y; Brown AM; Serbulea V; Bevan DR; Lynch KR; Santos WL
Eur J Med Chem; 2021 Feb; 212():113121. PubMed ID: 33445156
[TBL] [Abstract][Full Text] [Related]
7. Metastatic triple-negative breast cancer is dependent on SphKs/S1P signaling for growth and survival.
Maiti A; Takabe K; Hait NC
Cell Signal; 2017 Apr; 32():85-92. PubMed ID: 28108260
[TBL] [Abstract][Full Text] [Related]
8. Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1.
Schnute ME; McReynolds MD; Kasten T; Yates M; Jerome G; Rains JW; Hall T; Chrencik J; Kraus M; Cronin CN; Saabye M; Highkin MK; Broadus R; Ogawa S; Cukyne K; Zawadzke LE; Peterkin V; Iyanar K; Scholten JA; Wendling J; Fujiwara H; Nemirovskiy O; Wittwer AJ; Nagiec MM
Biochem J; 2012 May; 444(1):79-88. PubMed ID: 22397330
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationship studies of the lipophilic tail region of sphingosine kinase 2 inhibitors.
Congdon MD; Childress ES; Patwardhan NN; Gumkowski J; Morris EA; Kharel Y; Lynch KR; Santos WL
Bioorg Med Chem Lett; 2015 Nov; 25(21):4956-4960. PubMed ID: 25862200
[TBL] [Abstract][Full Text] [Related]
10. Building a better sphingosine kinase-1 inhibitor.
Lynch KR
Biochem J; 2012 May; 444(1):e1-2. PubMed ID: 22533672
[TBL] [Abstract][Full Text] [Related]
11. Sphingosine kinase inhibitors: a review of patent literature (2006-2015).
Lynch KR; Thorpe SB; Santos WL
Expert Opin Ther Pat; 2016 Dec; 26(12):1409-1416. PubMed ID: 27539678
[TBL] [Abstract][Full Text] [Related]
12. Sphingosine Kinase 1 Signaling in Breast Cancer: A Potential Target to Tackle Breast Cancer Stem Cells.
Hii LW; Chung FF; Mai CW; Ng PY; Leong CO
Front Mol Biosci; 2021; 8():748470. PubMed ID: 34820423
[TBL] [Abstract][Full Text] [Related]
13. Transforming Sphingosine Kinase 1 Inhibitors into Dual and Sphingosine Kinase 2 Selective Inhibitors: Design, Synthesis, and in Vivo Activity.
Childress ES; Kharel Y; Brown AM; Bevan DR; Lynch KR; Santos WL
J Med Chem; 2017 May; 60(9):3933-3957. PubMed ID: 28406646
[TBL] [Abstract][Full Text] [Related]
14. Design and Development of Novel Urea, Sulfonyltriurea, and Sulfonamide Derivatives as Potential Inhibitors of
Roy S; Mahapatra AD; Mohammad T; Gupta P; Alajmi MF; Hussain A; Rehman MT; Datta B; Hassan MI
Pharmaceuticals (Basel); 2020 Jun; 13(6):. PubMed ID: 32526899
[TBL] [Abstract][Full Text] [Related]
15. Roles of sphingosine-1-phosphate signaling in cancer.
Wang P; Yuan Y; Lin W; Zhong H; Xu K; Qi X
Cancer Cell Int; 2019; 19():295. PubMed ID: 31807117
[TBL] [Abstract][Full Text] [Related]
16. Sphingosine Kinase 2 Inhibitors: Rigid Aliphatic Tail Derivatives Deliver Potent and Selective Analogues.
Pashikanti S; Foster DJ; Kharel Y; Brown AM; Bevan DR; Lynch KR; Santos WL
ACS Bio Med Chem Au; 2022 Oct; 2(5):469-489. PubMed ID: 36281302
[TBL] [Abstract][Full Text] [Related]
17. Design of Sphingosine Kinases Inhibitors: Challenges and Recent Developments.
Magli E; Corvino A; Fiorino F; Frecentese F; Perissutti E; Saccone I; Santagada V; Caliendo G; Severino B
Curr Pharm Des; 2019; 25(9):956-968. PubMed ID: 30947653
[TBL] [Abstract][Full Text] [Related]
18. The sphingosine kinase 1 and S1P1 axis specifically counteracts LPS-induced IL-12p70 production in immune cells of the spleen.
Schröder M; Richter C; Juan MH; Maltusch K; Giegold O; Quintini G; Pfeilschifter JM; Huwiler A; Radeke HH
Mol Immunol; 2011 May; 48(9-10):1139-48. PubMed ID: 21435724
[TBL] [Abstract][Full Text] [Related]
19. Sphingosine Kinases/Sphingosine 1-Phosphate Signaling in Hepatic Lipid Metabolism.
Kwong EK; Li X; Hylemon PB; Zhou H
Curr Pharmacol Rep; 2017 Aug; 3():176-183. PubMed ID: 29130028
[TBL] [Abstract][Full Text] [Related]
20. Discovery, biological evaluation, and structure-activity relationship of amidine based sphingosine kinase inhibitors.
Mathews TP; Kennedy AJ; Kharel Y; Kennedy PC; Nicoara O; Sunkara M; Morris AJ; Wamhoff BR; Lynch KR; Macdonald TL
J Med Chem; 2010 Apr; 53(7):2766-78. PubMed ID: 20205392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
